PBAC's latest decision on Nivolumab plus ipilimumab: Recommended with restriction (2020). Considered for First-line treatment of previously untreated Stage IV (metastatic) non-small cell lung cancer (NSCLC) in patients without EGFR or ALK gene rearrangements, in combination with platinum-based doublet chemotherapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2020
Submissions
1
2020 → 2020
Eligible population
Adults with previously untreated Stage IV (metastatic) NSCLC without EGFR or ALK gene rearrangements, ECOG performance status 0 or 1, treated with nivolumab plus ipilimumab in combination with two cycles of platinum-based doublet chemotherapy.